Citadel Advisors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Citadel Advisors’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-18,891	Closed	-$40K	–	10353
2018 Q3	$40K	Sell	18,891 -664	-3%	-$1.59K	﹤0.01%	8854
2018 Q2	$45K	Sell	19,555 -35,023	-64%	-$102K	﹤0.01%	8461
2018 Q1	$174K	Buy	54,578 +10,000	+22%	+$27.6K	﹤0.01%	7446
2017 Q4	$183K	Buy	44,578 +10,991	+33%	+$47.8K	﹤0.01%	7177
2017 Q3	$152K	Sell	33,587 -12,410	-27%	-$50.3K	﹤0.01%	6848
2017 Q2	$154K	Buy	+45,997	New	+$191K	﹤0.01%	6723
2017 Q1	–	Sell	-18,306	Closed	-$161K	–	8575
2016 Q4	$141K	Buy	18,306 +5,533	+43%	+$50.8K	﹤0.01%	6538
2016 Q3	$146K	Buy	+12,773	New	+$149K	﹤0.01%	6491
2016 Q1	–	Sell	-5,648	Closed	-$66.3K	–	9262
2015 Q4	$127K	Buy	+5,648	New	+$116K	﹤0.01%	6423
2014 Q1	–	Sell	-8,953	Closed	-$264K	–	8338
2013 Q4	$264K	Buy	+8,953	New	+$164K	﹤0.01%	4727

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors's OMED Position: Q4 2018 in Review

Citadel Advisors sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 18,891 shares — an estimated $40K sold.

Citadel Advisors first reported a position in OMED in Q4 2013 and held it in 10 quarters. The position peaked at $264K in Q4 2013. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

Citadel Advisors reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Citadel Advisors sold 18,891 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $40K.
Citadel Advisors first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2013 and held it in 10 quarters.
Citadel Advisors's OncoMed Pharmaceuticals, Inc. position peaked at $264K in Q4 2013.
42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.